Keyphrases
17-estradiol
33%
Accelerated Growth
33%
Behavioral Improvement
33%
Bone Maturation
33%
Buserelin
100%
Chronic Administration
33%
Clinical Improvement
33%
D-Ser
33%
Gonadotropin Secretion
33%
Gonadotropins
66%
Growth Velocity
66%
Idiopathic Precocious Puberty
33%
Intranasal
33%
Intranasal Treatment
100%
LHRH Agonist
33%
Long-acting Analog
100%
Luteinizing Hormone
100%
Optimal Dose
33%
Parenteral Treatment
33%
Pituitary Gonadotropins
33%
Precocious Puberty
100%
Pubertal Development
33%
Puberty
33%
Safety Self-efficacy
33%
Sex Steroids
33%
Sexual Precocity
33%
Skeletal Maturity
33%
Subcutaneous Treatment
100%
Tanner Stage
33%
Testosterone
33%
Therapy Discontinuation
33%
Transient Acceleration
33%
Treatment Phase
33%
Unwanted Effects
33%
Withdrawal Bleeding
33%
Medicine and Dentistry
Bone Maturation
50%
Buserelin
75%
Chronic Drug Administration
25%
Diethylstilbestrol
25%
Gonadorelin
100%
Gonadorelin Agonist
25%
Gonadotropin
50%
Gonadotropin Release
25%
Growth Rate
50%
Optimal Drug Dose
25%
Parenteral Drug Administration
25%
Precocious Puberty
100%
Sex Hormone
25%
Withdrawal Bleeding
25%
Pharmacology, Toxicology and Pharmaceutical Science
Buserelin
75%
Diethylstilbestrol
25%
Gonadorelin
100%
Gonadorelin Agonist
25%
Gonadotropin
75%
Precocious Puberty
100%
Sex Hormone
25%
Withdrawal Bleeding
25%